Publications

Publications

337 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)

Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...

Report | 20-09-2021

GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

Zorginstituut Nederland has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat (Evrenzo®) can be ...

Report | 03-09-2021

Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

Zorginstituut Nederland has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) and two ...

Report | 11-08-2021

GVS advice on the reassessment of tafamidis (Vyndaqel®)

The Zorginstituut recommends not to include tafamidis (Vyndaqel®) in the GVS, unless a price reduction of at least 50% can be ...

Report | 11-08-2021

Advice on the reassessment of axicabtagene ciloleucel (Yescarta®)

Zorginstituut Nederland has carried out the reassessment of axicabtagene ciloleucel (Yescarta®).

Report | 26-07-2021

GVS advice on ferrimaltol (Feraccru®) for treating iron deficiency

Zorginstituut Nederland recommends that ferrimaltol (Feraccru®) should not be included in the Medicine Reimbursement System ...

Report | 26-07-2021

GVS advice on subcutaneous buprenorphine (Buvidal®)

Zorginstituut Nederland has completed its assessment whether the product subcutaneous buprenorphine (Buvidal®) is interchangeable ...

Report | 21-07-2021

Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)

Zorginstituut Nederland has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in the insured ...

Report | 21-07-2021

Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma

Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...

Report | 21-07-2021

Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer

Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...

Report | 21-07-2021